electroCore, Inc. (NASDAQ:ECOR – Get Free Report) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 43,000 shares, an increase of 64.1% from the October 15th total of 26,200 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 50,200 shares, the days-to-cover ratio is currently 0.9 days.
Institutional Investors Weigh In On electroCore
A number of institutional investors have recently made changes to their positions in ECOR. International Assets Investment Management LLC boosted its position in electroCore by 689.1% during the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock worth $3,864,000 after acquiring an additional 467,326 shares during the period. Renaissance Technologies LLC lifted its position in electroCore by 3.4% in the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock worth $442,000 after purchasing an additional 2,270 shares during the period. Finally, HighTower Advisors LLC bought a new position in electroCore during the 3rd quarter valued at $255,000. 26.74% of the stock is currently owned by institutional investors.
electroCore Stock Down 19.6 %
ECOR stock opened at $10.94 on Friday. electroCore has a 52-week low of $5.02 and a 52-week high of $14.20. The stock’s 50 day moving average is $8.89 and its two-hundred day moving average is $7.22. The company has a market capitalization of $70.56 million, a PE ratio of -5.98 and a beta of 0.56.
About electroCore
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Read More
- Five stocks we like better than electroCore
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Top-Performing Non-Leveraged ETFs This Year
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
